Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

EPMA J · 2012 · PMC3375104 · PMID 22738151

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

CTC enumeration as an intermediate endpoint biomarker Highly significant differences in survival based on changes in CTC counts following cytotoxic and hormone therapy have been observed.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.